Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | PRKCG | P05129 | 1/20 | 0.51 |
| ▸ | PRKACA | P17612 | 1/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | PRKX | P51817 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.51 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.51 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6230534 | 0.82 | NR1H4 (0.55) | ROCK2ROCK1MMP13MAPK1RPS6KA5 | |
| SCHEMBL6477764 | 0.78 | ROCK2 (0.50) | ROCK2ROCK1MMP13MAPK1RPS6KA5 | |
| SCHEMBL8359638 | 0.77 | ROCK2 (0.62) | ROCK2ROCK1MMP13MAPK1RPS6KA5 | |
| SCHEMBL6235225 | 0.77 | GAA (0.53) | CYP2C9ALDH1A1SMN1; SMN2LMNANAMPT | |
| SCHEMBL1161697 | 0.76 | MMP13 (0.82) | ROCK2ROCK1MMP13MAPK1RPS6KA5 | |
| SCHEMBL6231446 | 0.75 | GAA (0.56) | MMP13MAPK1CYP3A4ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6461896 | 0.74 | MMP13 (0.74) | ROCK2ROCK1MMP13MAPK1RPS6KA5 | |
| SCHEMBL17142140 | 0.74 | HDAC2 (0.64) | PPARGHDAC2HDAC8HDAC6ALDH1A1 | |
| SCHEMBL1569194 | 0.73 | ROCK2 (0.82) | ROCK2ROCK1MMP13MAPK1RPS6KA5 | |
| SCHEMBL11900328 | 0.73 | HDAC6 (0.87) | MMP13PPARGHDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1536786-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1531904-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6849648-B2 | Phenylene alkyne matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1434585-A1 | ALKYNE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2004007024-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006913-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030144274-A1 | Alkyne matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2003-07-31 | — | — | US | disclosed |
| WO-2003032999-A1 | ALKYNE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP11, MMP13, MMP10 | ROCK2 350/4885ROCK1 784/4885MMP13 2/4885 |
| US-20030144274-A1 | Alkyne matrix metalloproteinase inhibitors | MMP11, MMP13, MMP3 | ROCK2 171/4885ROCK1 60/4885MMP13 2/4885 |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP11, MMP13, MMP10 | ROCK2 222/4885ROCK1 719/4885MMP13 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.